ASAP is committed to accelerating the pace of discovery and informing a path to a cure for Parkinson’s disease through collaboration, research-enabling resources, and data sharing. We’ve created this catalog to showcase the research outputs and tools developed by ASAP-funded programs.
Non-ablative disease-modifying effects of magnetic resonance-guided focused ultrasound in neuromelanin-producing parkinsonian rodents
Preprint: The authors’ findings indicate that tFUS treatment applied at prodromal/early disease stages provides by itself extended structural and functional preservation of the nigrostriatal pathway in neuromelanin-producing parkinsonian rats without causing overt neuronal damage.
Preprint: Evidence is provided showing that intracellular aggregation of endogenous alpha-synuclein is triggered by NMel accumulation; therefore any therapeutic approach intended to decrease NMel levels may provide appealing choices for the successful implementation of novel PD therapeutics.
In vivo reduction of age-dependent neuromelanin accumulation mitigates features of Parkinson’s disease
Preprint: Using a newly developed rodent model, the authors assessed whether the intracellular buildup of neuromelanin that occurs with age can be slowed down in vivo to prevent or attenuate Parkinson’s disease. when neuromelanin reaches a specific threshold, it can trigger PD pathology in this animal model.
Protocol for stereotaxic rat brain surgery for Substantia Nigra targeting.
Determination of free and protein-bound DA and NE and their metabolites and oxidation products by UPLC-MS/MS method
Protocol for the determination of free and protein-bound DA and NE and their metabolites and oxidation products by UPLC-MS/MS method.
Protocol for stereologic count with StereoInvestigator.